Latest news with #Spevigo
Yahoo
a day ago
- Business
- Yahoo
LEO Pharma secures rights to Boehringer's Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim's psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. The transaction will see LEO gain the exclusive global licence for Spevigo, taking control of commercialisation and development rights. The full terms of the deal were not disclosed as both companies are privately owned, but LEO confirmed it is in line for milestone payments and royalties. The deal is expected to close in the second half of 2025. Spevigo is approved in the US, Japan, China and most European countries to treat generalised pustular psoriasis (GPP) flares, a rare but severe dermatological disease that can be fatal. It has also been approved in expanded indications in GPP in certain territories. LEO's new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor - a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. Indeed, GPP may not be the ceiling for Spevigo – LEO said there is an 'opportunity to investigate the potential of Spevigo in additional skin conditions with high unmet medical need in which IL-36 is implicated'. LEO calls Spevigo 'the flagship dermatology product' of Boehringer Ingelheim, though the drug's sales have not been publicly disclosed. Comparing sales from other drugs is tricky because Spevigo is the only US Food and Drug Administration (FDA)-approved treatment specifically for GPP. Boehringer Ingelheim's head of human pharma Shashank Deshpande said: 'Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid.' Adding Spevigo to its portfolio represents a strengthening of assets for dermatology specialist LEO. The Danish drugmaker has been building its pipeline amid reports it is planning an initial public offering (IPO) next year. Christophe Bourdon, who was appointed CEO in 2022 and tasked with turning the fortunes of the company around, has made no secret of public listing plans. In an interview with Bloomberg yesterday [14 July], Bourdon said market conditions and shareholders' wishes will decide the best timing for an IPO. The deal with Boehringer Ingelheim marks the second time LEO has signed a licensing agreement with a big pharma company in 2025. In January, Gilead Sciences offered a potential $1.7bn for LEO's preclinical STAT6 research programmes, which the dermatology company agreed to. As part of the deal, LEO received $250m in an upfront payment, boosting its cash on hand. "LEO Pharma secures rights to Boehringer's Spevigo for $105m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Bloomberg
2 days ago
- Business
- Bloomberg
LEO Pharma Adds Skin Drug from Boehringer as It Readies for IPO
LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the Danish dermatology specialist strengthens its portfolio ahead of a planned initial public offering in 2026. Under the deal, LEO Pharma will take over global commercialization and further development of the drug, which treats generalized pustular psoriasis, or GPP, a rare and potentially life-threatening condition, LEO said in press release on Monday. Boehringer will receive an upfront payment of €90 million ($110 million) and is eligible for future milestone and royalty payments.
Medical News Today
03-07-2025
- Health
- Medical News Today
Spevigo (spesolimab-sbzo) and cost
The cost of Spevigo can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you'll pay for cost and savingsAs with all medications, the cost of Spevigo can vary. Factors that may affect the price for Spevigo you'll pay include:your treatment planyour insurance coveragethe cost of the visit to your healthcare professional to receive Spevigo infusionswhether Spevigo has a savings program (see the 'Financial and insurance assistance' section)To find out what the cost of Spevigo will be for you, talk with your doctor, pharmacist, or insurance provider. This section also has information about how much you can save by using an Optum Perks coupons and savingsTo save money on your Spevigo prescription, explore these Optum Perks vs. biosimilar drugsSpevigo contains the active ingredient spesolimab-sbzo, and it's available only as a brand-name biologic drug. It doesn't come in a biosimilar version. A biosimilar medication is a drug that's similar to a brand-name biologic drug (the reference drug). Also, biosimilars tend to cost less than brand-name ARE COSTS DIFFERENT FOR BIOLOGIC DRUGS VS. BIOSIMILAR DRUGS?Biologic drugs can be expensive because of the research needed to test their safety and effectiveness. The manufacturer of a biologic drug can sell it for up to 12 years. When the biologic drug's patent expires, multiple manufacturers can create biosimilar versions. This marketplace competition may lead to lower costs for biosimilars. Also, because biosimilars are very similar to biologic drugs, they don't require the same costly and insurance assistanceIf you need financial support to pay for Spevigo, or if you need help understanding your insurance coverage, help is available. For example:A program called BI Solutions Plus is available for Spevigo. For more information and to find out whether you're eligible for support, call 833-773-8446 or visit the program websites provide details about drug assistance programs, ways to make the most of your insurance coverage, and links to savings cards and other services. Two such websites are: Medicine Assistance ToolNeedyMeds» Learn more about saving money on prescriptions with or without considerationsYou may want to consider the following information if you have insurance and receive a drug requires prior authorization but you start treatment without the prior approval, you could pay the full cost of the medication. You can ask your insurance company whether Spevigo requires prior of insurance coverage: Spevigo is given by your doctor or another healthcare professional. If you have insurance, the price of your Spevigo doses may be billed through your medical coverage instead of the prescription drug portion of your insurance plan. This depends on your specific insurance plan and where you receive your Spevigo doses, such as at your doctor's office, an infusion clinic, or a you have questions about this process, contact your doctor or your insurance Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
